Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense

2026-01-15 09:45:39 ET

Milestone Pharmaceuticals Inc. ( MIST ) was founded in 2003 and is based, jointly, in both Montreal and Charlotte, with its 30+ employees split between both locations. It is an early-stage biotech company that has developed a nasal spray based on a calcium channel blocker (etripamil, trademarked as Cardamyst) for on-demand/at-home use by patients to treat PSVT (paroxysmal supraventricular tachycardia) and atrial fibrillation with rapid ventricular rate (AFib-RVR). These are common heart conditions characterized by the sudden onset of an abnormal heart rhythm, and they affect millions of people in the U.S. and abroad. The drug works by blocking certain calcium channels in the heart, which slows down electrical signals in the atrioventricular node, thereby relaxing blood vessels. Etripamil helps the heart return to a normal rhythm by interrupting the abnormal electrical signals that patients with PSVT experience. Given some recent news, I’d like to take the opportunity to revisit this company and offer a more nuanced analysis....

Read the full article on Seeking Alpha

For further details see: